Complement inhibition in C3 glomerulopathy

Seminars in Immunology

Volumn 28, Issue 3, 2016, Pages 241-249

  Nester, Carla M ^a   Smith, Richard J H ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

C3 glomerulonephritis; C3 glomerulopathy; Complement; Dense deposit disease; Eculizumab; Membranoproliferative glomerulonephritis

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C3; ECULIZUMAB; COMPLEMENT INHIBITOR;

COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; GLOMERULOPATHY; HUMAN; NONHUMAN; REVIEW; ANIMAL; COMPLEMENT ALTERNATIVE PATHWAY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; BIOMARKERS; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; GENE FREQUENCY; GENOTYPE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOTHERAPY; KIDNEY; POLYMORPHISM, GENETIC;

EID: 84991834342     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.06.002     Document Type: Review

References (72)

1. [1] Pickering, M.C., D'Agati, V.D., Nester, C.M., Smith, R.J., Haas, M., Appel, G.B., Alpers, C.E., Bajema, I.M., Bedrosian, C., Braun, M., Doyle, M., Fakhouri, F., Fervenza, F.C., Fogo, A.B., Fremeaux-Bacchi, V., Gale, D.P., Goicoechea de Jorge, E., Griffin, G., Harris, C.L., Holers, V.M., Johnson, S., Lavin, P.J., Medjeral-Thomas, N., Paul Morgan, B., Nast, C.C., Noel, L.H., Peters, D.K., Rodriguez de Cordoba, S., Servais, A., Sethi, S., Song, W.C., Tamburini, P., Thurman, J.M., Zavros, M., Cook, H.T., C3 glomerulopathy: consensus report. Kidney Int. 84:6 (2013), 1079–1089.
2. [2] Sethi, S., Haas, M., Markowitz, G.S., D'Agati, V.D., Rennke, H.G., Jennette, J.C., Bajema, I.M., Alpers, C.E., Chang, A., Cornell, L.D., Cosio, F.G., Fogo, A.B., Glassock, R.J., Hariharan, S., Kambham, N., Lager, D.J., Leung, N., Mengel, M., Nath, K.A., Roberts, I.S., Rovin, B.H., Seshan, S.V., Smith, R.J., Walker, P.D., Winearls, C.G., Appel, G.B., Alexander, M.P., Cattran, D.C., Casado, C.A., Cook, H.T., De Vriese, A.S., Radhakrishnan, J., Racusen, L.C., Ronco, P., Fervenza, F.C., Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J. Am. Soc. Nephrol. 27:5 (2016), 1278–1287.
3. [3] Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11:9 (2010), 785–797.
4. [4] Jore, M.M., Johnson, S., Sheppard, D., Barber, N.M., Li, Y.I., Nunn, M.A., Elmlund, H., Lea, S.M., Structural basis for therapeutic inhibition of complement C5. Nat. Struct. Mol. Biol. 23:5 (2016), 378–386.
5. [5] Kohl, J., The role of complement in danger sensing and transmission. Immunol. Res. 34:2 (2006), 157–176.
6. [6] Klos, A., Wende, E., Wareham, K.J., Monk, P.N., International union of basic and clinical pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65:1 (2013), 500–543.
7. [7] Zhang, Y., Nester, C.M., Martin, B., Skjoedt, M.O., Meyer, N.C., Shao, D., Borsa, N., Palarasah, Y., Smith, R.J., Defining the complement biomarker profile of C3 glomerulopathy. Clin. J. Am. Soc. Nephrol. 9:11 (2014), 1876–1882.
8. [8] Hou, J., Markowitz, G.S., Bomback, A.S., Appel, G.B., Herlitz, L.C., Barry Stokes, M., D'Agati, V.D., Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85:2 (2014), 450–456.
9. [9] Servais, A., Noel, L.H., Roumenina, L.T., Le Quintrec, M., Ngo, S., Dragon-Durey, M.A., Macher, M.A., Zuber, J., Karras, A., Provot, F., Moulin, B., Grunfeld, J.P., Niaudet, P., Lesavre, P., Fremeaux-Bacchi, V., Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82:4 (2012), 454–464.
10. [10] Lu, D.F., McCarthy, A.M., Lanning, L.D., Delaney, C., Porter, C., A descriptive study of individuals with membranoproliferative glomerulonephritis. Nephrol. Nurs. J. 34:3 (2007), 295–302 (quiz 303).
11. [11] Servais, A., Fremeaux-Bacchi, V., Lequintrec, M., Salomon, R., Blouin, J., Knebelmann, B., Grunfeld, J.P., Lesavre, P., Noel, L.H., Fakhouri, F., Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 44:3 (2007), 193–199.
12. [12] Zand, L., Kattah, A., Fervenza, F.C., Smith, R.J., Nasr, S.H., Zhang, Y., Vrana, J.A., Leung, N., Cornell, L.D., Sethi, S., C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am. J. Kidney Dis. 62:3 (2013), 506–514.
13. [13] Sethi, S., Sukov, W.R., Zhang, Y., Fervenza, F.C., Lager, D.J., Miller, D.V., Cornell, L.D., Krishnan, S.G., Smith, R.J., Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am. J. Kidney Dis. 56:5 (2010), 977–982.
14. [14] Bridoux, F., Desport, E., Fremeaux-Bacchi, V., Chong, C.F., Gombert, J.M., Lacombe, C., Quellard, N., Touchard, G., Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?. Clin. J. Am. Soc. Nephrol. 6:9 (2011), 2165–2174.
15. [15] Meri, S., Koistinen, V., Miettinen, A., Tornroth, T., Seppala, I.J., Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J. Exp. Med. 175:4 (1992), 939–950.
16. [16] Jokiranta, T.S., Solomon, A., Pangburn, M.K., Zipfel, P.F., Meri, S., Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163:8 (1999), 4590–4596.
17. [17] Nasr, S.H., Valeri, A.M., Appel, G.B., Sherwinter, J., Stokes, M.B., Said, S.M., Markowitz, G.S., D'Agati, V.D., Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. A. S. Nephrol. 4:1 (2009), 22–32.
18. [18] Lu, D.F., Moon, M., Lanning, L.D., McCarthy, A.M., Smith, R.J., Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr. Nephrol. 27:5 (2012), 773–781.
19. [19] Medjeral-Thomas, N.R., O'Shaughnessy, M.M., O'Regan, J.A., Traynor, C., Flanagan, M., Wong, L., Teoh, C.W., Awan, A., Waldron, M., Cairns, T., O'Kelly, P., Dorman, A.M., Pickering, M.C., Conlon, P.J., Cook, H.T., C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 9:1 (2014), 46–53.
20. [20] Schwertz, R., de Jong, R., Gretz, N., Kirschfink, M., Anders, D., Scharer, K., Outcome of idiopathic membranoproliferative glomerulonephritis in children. Arbeitsgemeinschaft Padiatrische Nephrologie. Acta Paediatr. 85:3 (1996), 308–312.
21. [21] Smith, R.J., Alexander, J., Barlow, P.N., Botto, M., Cassavant, T.L., Cook, H.T., de Cordoba, S.R., Hageman, G.S., Jokiranta, T.S., Kimberling, W.J., Lambris, J.D., Lanning, L.D., Levidiotis, V., Licht, C., Lutz, H.U., Meri, S., Pickering, M.C., Quigg, R.J., Rops, A.L., Salant, D.J., Sethi, S., Thurman, J.M., Tully, H.F., Tully, S.P., van der Vlag, J., Walker, P.D., Wurzner, R., Zipfel, P.F., Dense, G., Deposit disease focus, new approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18:9 (2007), 2447–2456.
22. [22] Jansen, J.H., Hogasen, K., Harboe, M., Hovig, T., In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int. 53:2 (1998), 331–349.
23. [23] Hegasy, G.A., Manuelian, T., Hogasen, K., Jansen, J.H., Zipfel, P.F., The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am. J. Pathol. 161:6 (2002), 2027–2034.
24. [24] Jansen, J.H., Porcine membranoproliferative glomerulonephritis with intramembranous dense deposits (porcine dense deposit disease). APMIS 101:4 (1993), 281–289.
25. [25] Pickering, M.C., Cook, H.T., Warren, J., Bygrave, A.E., Moss, J., Walport, M.J., Botto, M., Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 31:4 (2002), 424–428.
26. [26] Fakhouri, F., de Jorge, E.G., Brune, F., Azam, P., Cook, H.T., Pickering, M.C., Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int. 78:3 (2010), 279–286.
27. [27] Rose, K.L., Paixao-Cavalcante, D., Fish, J., Manderson, A.P., Malik, T.H., Bygrave, A.E., Lin, T., Sacks, S.H., Walport, M.J., Cook, H.T., Botto, M., Pickering, M.C., Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Invest. 118:2 (2008), 608–618.
28. [28] Pickering, M.C., Warren, J., Rose, K.L., Carlucci, F., Wang, Y., Walport, M.J., Cook, H.T., Botto, M., Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 103:25 (2006), 9649–9654.
29. [29] Levy, M., Halbwachs-Mecarelli, L., Gubler, M.C., Kohout, G., Bensenouci, A., Niaudet, P., Hauptmann, G., Lesavre, P., H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int. 30:6 (1986), 949–956.
30. [30] Manuelian, T., Hellwage, J., Meri, S., Caprioli, J., Noris, M., Heinen, S., Jozsi, M., Neumann, H.P., Remuzzi, G., Zipfel, P.F., Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111:8 (2003), 1181–1190.
31. [31] Ault, B.H., Schmidt, B.Z., Fowler, N.L., Kashtan, C.E., Ahmed, A.E., Vogt, B.A., Colten, H.R., Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J. Biol. Chem. 272:40 (1997), 25168–25175.
32. [32] Bomback, A.S., Smith, R.J., Barile, G.R., Zhang, Y., Heher, E.C., Herlitz, L., Stokes, M.B., Markowitz, G.S., D'Agati, V.D., Canetta, P.A., Radhakrishnan, J., Appel, G.B., Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 7:5 (2012), 748–756.
33. [33] Dragon-Durey, M.A., Blanc, C., Marliot, F., Loirat, C., Blouin, J., Sautes-Fridman, C., Fridman, W.H., Fremeaux-Bacchi, V., The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 46:7 (2009), 447–450.
34. [34] Licht, C., Heinen, S., Jozsi, M., Loschmann, I., Saunders, R.E., Perkins, S.J., Waldherr, R., Skerka, C., Kirschfink, M., Hoppe, B., Zipfel, P.F., Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 70:1 (2006), 42–50.
35. [35] Servais, A., Noel, L.H., Dragon-Durey, M.A., Gubler, M.C., Remy, P., Buob, D., Cordonnier, C., Makdassi, R., Jaber, W., Boulanger, E., Lesavre, P., Fremeaux-Bacchi, V., Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum. Pathol. 42:9 (2011), 1305–1311.
36. [36] Schejbel, L., Schmidt, I.M., Kirchhoff, M., Andersen, C.B., Marquart, H.V., Zipfel, P., Garred, P., Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun. 12:2 (2011), 90–99.
37. [37] Schmidt, B.Z., Fowler, N.L., Hidvegi, T., Perlmutter, D.H., Colten, H.R., Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency. J. Biol. Chem. 274:17 (1999), 11782–11788.
38. [38] Vogt, B.A., Wyatt, R.J., Burke, B.A., Simonton, S.C., Kashtan, C.E., Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr. Nephrol. 9:1 (1995), 11–15.
39. [39] Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., Piras, R., Donadelli, R., Maranta, R., van der Meer, I., Conway, E.M., Zipfel, P.F., Goodship, T.H., Remuzzi, G., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5:10 (2010), 1844–1859.
40. [40] Martinez-Barricarte, R., Heurich, M., Valdes-Canedo, F., Vazquez-Martul, E., Torreira, E., Montes, T., Tortajada, A., Pinto, S., Lopez-Trascasa, M., Morgan, B.P., Llorca, O., Harris, C.L., Rodriguez de Cordoba, S., Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120:10 (2010), 3702–3712.
41. [41] Imamura, H., Konomoto, T., Tanaka, E., Hisano, S., Yoshida, Y., Fujimura, Y., Miyata, T., Nunoi, H., Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrol. Dial. Transplant. 30:5 (2015), 862–864.
42. [42] Chen, Q., Wiesener, M., Eberhardt, H.U., Hartmann, A., Uzonyi, B., Kirschfink, M., Amann, K., Buettner, M., Goodship, T., Hugo, C., Skerka, C., Zipfel, P.F., Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J. Clin. Invest. 124:1 (2014), 145–155.
43. [43] Eberhardt, H.U., Buhlmann, D., Hortschansky, P., Chen, Q., Bohm, S., Kemper, M.J., Wallich, R., Hartmann, A., Hallstrom, T., Zipfel, P.F., Skerka, C., Human factor H-related protein 2 (CFHR2) regulates complement activation. PLoS One, 8(11), 2013, e78617.
44. [44] Besbas, N., Gulhan, B., Gucer, S., Korkmaz, E., Ozaltin, F., A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J. Nephrol. 27:4 (2014), 457–460.
45. [45] Gale, D.P., The identification of CFHR5 nephropathy. J. R. Soc. Med. 104:5 (2011), 186–190.
46. [46] Athanasiou, Y., Voskarides, K., Gale, D.P., Damianou, L., Patsias, C., Zavros, M., Maxwell, P.H., Cook, H.T., Demosthenous, P., Hadjisavvas, A., Kyriacou, K., Zouvani, I., Pierides, A., Deltas, C., Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin. J. Am. Soc. Nephrol. 6:6 (2011), 1436–1446.
47. [47] Medjeral-Thomas, N., Malik, T.H., Patel, M.P., Toth, T., Cook, H.T., Tomson, C., Pickering, M.C., A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int. 85:4 (2014), 933–937.
48. [48] Tortajada, A., Yebenes, H., Abarrategui-Garrido, C., Anter, J., Garcia-Fernandez, J.M., Martinez-Barricarte, R., Alba-Dominguez, M., Malik, T.H., Bedoya, R., Cabrera Perez, R., Lopez Trascasa, M., Pickering, M.C., Harris, C.L., Sanchez-Corral, P., Llorca, O., Rodriguez de Cordoba, S., C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 123:6 (2013), 2434–2446.
49. [49] Zhang, Y., Meyer, N.C., Wang, K., Nishimura, C., Frees, K., Jones, M., Katz, L.M., Sethi, S., Smith, R.J., Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 7:2 (2012), 265–274.
50. [50] Malik, T.H., Lavin, P.J., Goicoechea de Jorge, E., Vernon, K.A., Rose, K.L., Patel, M.P., de Leeuw, M., Neary, J.J., Conlon, P.J., Winn, M.P., Pickering, M.C., A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 23:7 (2012), 1155–1160.
51. [51] Goicoechea de Jorge, E., Caesar, J.J., Malik, T.H., Patel, M., Colledge, M., Johnson, S., Hakobyan, S., Morgan, B.P., Harris, C.L., Pickering, M.C., Lea, S.M., Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. U. S. A. 110:12 (2013), 4685–4690.
52. [52] Iatropoulos, P., Noris, M., Mele, C., Piras, R., Valoti, E., Bresin, E., Curreri, M., Mondo, E., Zito, A., Gamba, S., Bettoni, S., Murer, L., Fremeaux-Bacchi, V., Vivarelli, M., Emma, F., Daina, E., Remuzzi, G., Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol. Immunol. 71 (2016), 131–142.
53. [53] Strobel, S., Zimmering, M., Papp, K., Prechl, J., Jozsi, M., Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 47:7-8 (2010), 1476–1483.
54. [54] Ohi, H., Yasugi, T., Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin. Exp. Immunol. 95:2 (1994), 316–321.
55. [55] Tanuma, Y., Ohi, H., Watanabe, S., Seki, M., Hatano, M., C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Clin. Exp. Immunol. 76:1 (1989), 82–85.
56. [56] Bonucchi, D., Leonelli, M., Damiano, F., Granito, M., Ghiandai, G., De Amicis, S., Americo, C., Ligabue, G., Albertazzi, V., Cappelli, G., [Post-transplant recurrence of glomerulonephritis: a complex clinical case]. G Ital. Nefrol. 27:Suppl. 52 (2010), S82–4.
57. [57] Daina, E., Noris, M., Remuzzi, G., Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 366:12 (2012), 1161–1163.
58. [58] Garnier, A.S., Augusto, J.F., Pellier, I., Subra, J.F., Sayegh, J., Successful long-term outcome of kidney transplantation in a patient with X-linked thrombocytopenia: 9-year follow-up. Transplantation 98:6 (2014), e57–8.
59. [59] Gurkan, S., Fyfe, B., Weiss, L., Xiao, X., Zhang, Y., Smith, R.J., Eculizumab and recurrent C3 glomerulonephritis. Pediatr. Nephrol. 28:10 (2013), 1975–1981.
60. [60] Herlitz, L.C., Bomback, A.S., Markowitz, G.S., Stokes, M.B., Smith, R.N., Colvin, R.B., Appel, G.B., D'Agati, V.D., Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 23:7 (2012), 1229–1237.
61. [61] Inman, M., Prater, G., Fatima, H., Wallace, E., Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin. Kidney J. 8:4 (2015), 445–448.
62. [62] Kerns, E., Rozansky, D., Troxell, M.L., Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr. Nephrol. 28:11 (2013), 2227–2231.
63. [63] Le Quintrec, M., Lionet, A., Kandel, C., Bourdon, F., Gnemmi, V., Colombat, M., Goujon, J.M., Fremeaux-Bacchi, V., Fakhouri, F., Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am. J. Kidney Dis. 65:3 (2015), 484–489.
64. [64] McCaughan, J.A., O'Rourke, D.M., Courtney, A.E., Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am. J. Transplant. 12:4 (2012), 1046–1051.
65. [65] Oosterveld, M.J., Garrelfs, M.R., Hoppe, B., Florquin, S., Roelofs, J.J., van den Heuvel, L.P., Amann, K., Davin, J.C., Bouts, A.H., Schriemer, P.J., Groothoff, J.W., Eculizumab in pediatric dense deposit disease. Clin. J. Am. Soc. Nephrol. 10:10 (2015), 1773–1782.
66. [66] Ozkaya, O., Nalcacioglu, H., Tekcan, D., Genc, G., Meydan, B.C., Ozdemir, B.H., Baysal, M.K., Keceligil, H.T., Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr. Nephrol. 29:7 (2014), 1283–1287.
67. [67] Radhakrishnan, S., Lunn, A., Kirschfink, M., Thorner, P., Hebert, D., Langlois, V., Pluthero, F., Licht, C., Eculizumab and refractory membranoproliferative glomerulonephritis. N. Engl. J. Med. 366:12 (2012), 1165–1166.
68. [68] Rousset-Rouviere, C., Cailliez, M., Garaix, F., Bruno, D., Laurent, D., Tsimaratos, M., Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr. Nephrol. 29:6 (2014), 1107–1111.
69. [69] Sanchez-Moreno, A., De la Cerda, F., Cabrera, R., Fijo, J., Lopez-Trascasa, M., Bedoya, R., Rodriguez de Cordoba, S., Ybot-Gonzalez, P., Eculizumab in dense-deposit disease after renal transplantation. Pediatr. Nephrol. 29:10 (2014), 2055–2059.
70. [70] Vivarelli, M., Pasini, A., Emma, F., Eculizumab for the treatment of dense-deposit disease. N. Engl. J. Med. 366:12 (2012), 1163–1165.
71. [71] Zhang, Y., Nester, C.M., Holanda, D.G., Marsh, H.C., Hammond, R.A., Thomas, L.J., Meyer, N.C., Hunsicker, L.G., Sethi, S., Smith, R.J., Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J. Am. Soc. Nephrol. 24:11 (2013), 1820–1829.
72. [72] Zhang, Y., Shao, D., Ricklin, D., Hilkin, B.M., Nester, C.M., Lambris, J.D., Smith, R.J., Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 220:8 (2015), 993–998.